{"title":"Tofacitinib for the Treatment of Primary Localized Cutaneous Amyloidosis","authors":"Qin-Xiao Wang, Hai-Yang He, Ying-Luo Niu, Sheng Fang","doi":"10.1111/1346-8138.17869","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disorder that can cause persistent pruritus and cosmetic disfigurement and remains challenging to treat. Tofacitinib, an oral Janus kinase inhibitor, has shown potential therapeutic benefits for PLCA. We conducted a retrospective study of 24 patients with PLCA treated with tofacitinib (10 mg/day) at our dermatology clinic. Disease severity was assessed using body surface area (BSA), Peak Pruritus Numerical Rating Scale (PP-NRS), and Investigator Global Assessment (IGA) scores. Significant improvements were observed in BSA (<i>p</i> < 0.05), PP-NRS (<i>p</i> < 0.001), and IGA (<i>p</i> < 0.01) at week 4. Treatment was well tolerated, with no serious adverse events leading to discontinuation. The findings of this study suggest that tofacitinib could be an appealing approach for treating PLCA. Further large-scale, randomized controlled trials are necessary to confirm its long-term efficacy and safety.</p>\n </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 9","pages":"1461-1464"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.17869","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Primary localized cutaneous amyloidosis (PLCA) is a chronic skin disorder that can cause persistent pruritus and cosmetic disfigurement and remains challenging to treat. Tofacitinib, an oral Janus kinase inhibitor, has shown potential therapeutic benefits for PLCA. We conducted a retrospective study of 24 patients with PLCA treated with tofacitinib (10 mg/day) at our dermatology clinic. Disease severity was assessed using body surface area (BSA), Peak Pruritus Numerical Rating Scale (PP-NRS), and Investigator Global Assessment (IGA) scores. Significant improvements were observed in BSA (p < 0.05), PP-NRS (p < 0.001), and IGA (p < 0.01) at week 4. Treatment was well tolerated, with no serious adverse events leading to discontinuation. The findings of this study suggest that tofacitinib could be an appealing approach for treating PLCA. Further large-scale, randomized controlled trials are necessary to confirm its long-term efficacy and safety.
期刊介绍：
The Journal of Dermatology is the official peer-reviewed publication of the Japanese Dermatological Association and the Asian Dermatological Association. The journal aims to provide a forum for the exchange of information about new and significant research in dermatology and to promote the discipline of dermatology in Japan and throughout the world. Research articles are supplemented by reviews, theoretical articles, special features, commentaries, book reviews and proceedings of workshops and conferences.
Preliminary or short reports and letters to the editor of two printed pages or less will be published as soon as possible. Papers in all fields of dermatology will be considered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
